There is a particular kind of silence that settles over a cervical screening appointment. The paper sheet, the cold instrument, the practised brightness of the nurse, the request to move down the table - and beneath it all, in a great many women, a quiet wish to be somewhere, anywhere, else.
For most, it is an inconvenience endured every few years. For others, it is the reason they never come at all. The speculum, that splayed metal or plastic duckbill, has barely changed since a nineteenth-century surgeon designed it on enslaved women without anaesthetic. It remains, two centuries on, the gateway to one of the most successful cancer-prevention programmes ever devised - and, for about a third of the women who are invited, a gate they decline to walk through.
Those women are not a rounding error. They are, disproportionately, the ones the programme most needs to reach: women who have been hurt before, women without the hours to spare, women for whom the clinic is far away or simply unwelcoming. Cervical cancer is among the most preventable of all cancers; nearly all of it is caused by a single persistent virus that screening is very good at catching. The tragedy is not that we lack the science. It is that the science waits in a room many women will not enter.
This is the problem we set out to solve at Daye, and our answer has a kind of plainness that, on reflection, looks like nerve. We did not invent a new machine. We took the most familiar object in women's health - the tampon, a thing the great majority of women already know how to use without instruction or embarrassment - and asked it to gather evidence. Insert it, wear it briefly, seal it into a pouch, drop it in the post. From that single sample, a laboratory can now read whether high-risk HPV is present, screen for a range of sexually transmitted infections, and describe the bacterial ecology of the vaginal microbiome. No stirrups. No stranger. No appointment that has to be, in some cases, endured.
This idea has now crossed the line that separates a promising product from a medical one. Our Diagnostic Tampon is now CE- and UKCA-marked under the EU Medical Device Regulation, and the tests it feeds run on CE-marked diagnostic assays certified under the In Vitro Diagnostic Regulation - the same regulatory framework that governs tests used across the NHS and Europe's hospitals.
The distinction is not bureaucratic trivia. A great deal of what is sold to women under the banner of wellness is accountable to no one; it asserts, and we are invited to believe. Medical-device and diagnostic regulation are the opposite of an assertion. They require independent scrutiny of the tests and the manufacturing, and evidence that the thing does what it says, reliably, sample after sample. For a test a woman performs alone, in her bathroom, bedroom or living room, that reliability is the entire point.
What is quietly radical here, I think, is less the device than the relocation. For a century, the authority to read a woman's body has lived in the clinic, with its schedule and its instruments and its particular discomforts. We are proposing that some of that authority can move. Into the home, into the hands of the woman herself, without any loss of rigour.
And the tampon, it turns out, may have more to say than we expected. The vaginal canal is not a sealed compartment; it collects molecular signals that drift down from higher in the reproductive tract. Three of the world's leading cancer centres have independently adopted our device to hunt for the fingerprints of endometrial and ovarian cancers, two diseases for which no validated screening test yet exists, and which are therefore usually found late, when they are hardest to survive. None of this is settled; it is research, with all the caution that word demands. But the direction is striking. The instrument designed to reach women who avoid the clinic may also, in time, reach cancers that hide from it.
I am wary of overselling this. The temptation in women's health - a field starved of attention and funding for so long that any progress feels like a revolution - is real, and I feel it too. The honest framing is narrower and, in its way, more durable. A test like this does not abolish the screening programme; it extends its reach to the women standing outside it. It does not promise certainty; it offers a result a woman and her clinician can trust, obtained on terms she can accept. The regulators have now said as much.
There is something fitting in the ordinariness of the object at the centre of all this. We started Daye believing that women's health, done well, is comprehensive - that vaginal, hormonal, sexual and reproductive health belong together, close to home, rather than scattered across appointments a woman has to chase. Medicine's grand advances tend to arrive looking grand. This one arrives looking like something already in the bathroom drawer - which is, of course, exactly why it might work.